Four Years Off the Drug, and a Question Cladribine Was Never Built to Answer Twice
Two courses, four years ago, and nothing since — that was the whole design. One new lesion now has to be read against a drug built to keep working after it stops being given, which makes it genuinely unclear whether the effect is lapsing or this is the background noise any therapy produces.
A.N. is 33, a landscape architect, and came home three weeks ago from eight months on a public-park redesign abroad to a stack of deferred appointments — among them the four-year surveillance MRI she was already late for. She finished her second and final planned course of cladribine four years ago. Two short annual pulses were meant to be the entire treatment, not the start of anything ongoing, and for four years the scans and her symptoms both agreed. Today's shows one new non-enhancing T2 lesion, in a woman who feels entirely well and has nothing new on exam.
Reading that finding is harder than it would be on a continuously dosed drug, and the reason is the drug's own design. Cladribine produces a selective, delayed pattern of lymphocyte depletion and reconstitution intended to hold disease well past the treatment window; the CLARITY Extension followed patients two further years and found sustained efficacy without a mandated third course, though the population followed was selected for having stayed stable, which she has not. The label goes further — the cumulative 3.5mg/kg is the approved course, and reinitiating more than two years out has not been studied at all. Meanwhile the variable that the whole re-dosing rationale rests on has never been measured in her. Nobody has rechecked her T- and B-cell subsets since course two. There is a total lymphocyte count, comfortably normal, and MAGNIFY-MS showed that a normal total says very little about where an individual sits — B cells return well ahead of the T-cell compartment, and the spread between people is wide. The group is deciding what one lesion means without the one number that would tell them.
Reviewing the four-year surveillance MRI
I'd retreat her with a third course, on the same pulsed schedule. A new lesion is a new lesion, and cladribine's own mechanism was specifically designed to permit re-dosing once surveillance suggests control is lapsing — the CLARITY Extension data showing continued efficacy without mandatory retreatment came from patients who stayed stable. She hasn't.
If this were her third or fourth new lesion in the past year, I'd have no hesitation at all — it's the fact that this is a single finding, in an asymptomatic patient, that keeps me from calling this a closed question rather than an opening one.
One new, non-enhancing lesion four years off-drug, in an asymptomatic patient with no relapses in the interval, isn't by itself evidence the drug's effect has failed. Real-world registries following patients well past their second course have generally shown sustained low relapse rates without needing to resume dosing on this schedule. And the label is not silent here: cladribine tablets are approved as a cumulative 3.5mg/kg over two courses, and the safety and efficacy of reinitiating more than two years after completing them has not been established. A third course at four years isn't just unusual — it's outside what has been studied.
I'm genuinely closer to your position than I'm making it sound — this really is a single data point cutting against an otherwise strong multi-year pattern, and I wouldn't call retreatment wrong. I'd just want more than one lesion before committing to another full course on a drug built around not needing continuous dosing.
Neither of you has actually looked at the variable cladribine's re-dosing rationale is built on — her T- and B-cell reconstitution kinetics specifically, not just a total lymphocyte count. MAGNIFY-MS, which tracked lymphocyte subset repopulation after each cladribine course, showed real person-to-person variability in how quickly and how completely that recovery happens — B cells return well before the T-cell compartment does, and the spread between individuals is wide enough that a normal total count tells you almost nothing about where any one patient sits.
This doesn't resolve the disagreement between you two, and I don't think it should yet — it just means the actual mechanistic question underneath both of your positions hasn't been checked. If her reconstitution pattern looks atypical for someone four years out, that would support retreatment on genuinely mechanistic grounds rather than the lesion count alone.
Agreed: lymphocyte subset panel drawn today, MRI surveillance accelerated to six months, and no retreatment decision made until the subset result is in hand. The MS Neurologist's case for retreatment was not overruled — it remains the group's leading plan if her reconstitution pattern looks atypical, held rather than acted on today for lack of the specific data that would confirm it.
Not agreed, and left open deliberately: what threshold in that subset panel, once it returns, would actually tip the group toward a third course versus continued surveillance. That threshold wasn't set today because nobody in the room had a confident, evidence-grounded number to propose — the group chose to look at her actual result first rather than pre-commit to a cutoff none of them could fully defend yet.